Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $564M | $636M | $713M | $785M | $789M | $958M | $1.02B | $1.57B | $2.52B | $2.94B |
| Revenue growth | — | 12.8% | 12.1% | 10.2% | 0.5% | 21.4% | 6.8% | 53.3% | 60.6% | 16.7% |
| Gross profit | $429M | $486M | $554M | $605M | $572M | $719M | $759M | $1.02B | — | — |
| Gross margin | 76.1% | 76.3% | 77.6% | 77.1% | 72.4% | 75.0% | 74.2% | 65.1% | — | — |
| Operating income | $154M | $162M | $169M | $172M | $111M | $172M | $228M | $133M | $166M | $480M |
| Operating margin | 27.3% | 25.4% | 23.7% | 21.9% | 14.1% | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| Net income | $104M | $107M | $156M | $155M | $102M | $149M | $190M | $123M | $103M | $538M |
| Net margin | 18.5% | 16.9% | 21.9% | 19.8% | 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
| EPS (diluted) | $1.08 | $1.10 | $1.54 | $1.52 | $1.01 | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $148M | $159M | $182M | $172M | $199M | $276M | $178M | $243M | $521M | $753M |
| Capital expenditures | $40.9M | $51.3M | $59.7M | $70.8M | $63.7M | $56.9M | $74.0M | $78.3M | $115M | $165M |
| Free cash flow | $107M | $108M | $122M | $101M | $135M | $219M | $104M | $165M | $405M | $589M |
| Share buybacks | — | — | — | — | $105M | — | $144M | $226M | $85.8M | $300M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $67.0M | $119M | $140M | $195M | $239M | $193M | $150M | $467M | $784M | $526M |
| Total assets | $928M | $1.08B | $1.30B | $1.53B | $1.68B | $1.96B | $2.08B | $5.09B | $5.25B | $5.30B |
| Total liabilities | $95.6M | $111M | $115M | $130M | $173M | $216M | $230M | $1.09B | $1.07B | $730M |
| Shareholders' equity | $832M | $968M | $1.19B | $1.40B | $1.51B | $1.74B | $1.85B | $4.00B | $4.18B | $4.57B |
| Retained earnings | $629M | $736M | $893M | $1.05B | $1.05B | $1.19B | $1.24B | $1.14B | $1.15B | $1.39B |
| Shares (wtd avg diluted) | 96.4M | 97.9M | 101M | 102M | 101M | 104M | 103M | 115M | 138M | 137M |
Every figure is extracted from GLOBUS MEDICAL INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.